Mice with the CHEK2*1100delC SNP are predisposed to cancer with a strong gender bias

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 40, 2009, Pages 17111-17116

  Bahassi, El Mustapha ^a   Robbins, Susan B ^a   Moying, Yin ^a   Boivin, Gregory P ^b   Kuiper, Raoul ^c   Van Steeg, Harry ^c   Stambrook, Peter J ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b WRIGHT STATE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Cancer predisposition; Cdc25A; Polymorphism

Indexed keywords

7,12 DIMETHYLBENZ[A]ANTHRACENE; CARCINOGEN; CELL CYCLE PROTEIN; CELL CYCLE PROTEIN 25A; CHECKPOINT KINASE 2; CYSTEINE; DOUBLE STRANDED DNA; UNCLASSIFIED DRUG; CDC25A PROTEIN, MOUSE; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE PHOSPHATASE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST TUMOR; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; EMBRYO CELL; FEMALE; FIBROBLAST; GENDER BIAS; GENE DELETION; GENE FREQUENCY; GENETIC VARIABILITY; GENOMIC INSTABILITY; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; LATENT PERIOD; LIFESPAN; MALE; MOUSE; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; ANIMAL; CHEMICALLY INDUCED DISORDER; GENETIC PREDISPOSITION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RISK FACTOR; SEX DIFFERENCE; TIME; WESTERN BLOTTING;

MUS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; BLOTTING, WESTERN; CDC25 PHOSPHATASES; FEMALE; FIBROBLASTS; GENE DELETION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; IMMUNOHISTOCHEMISTRY; MALE; MICE; NEOPLASMS; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN-SERINE-THREONINE KINASES; RISK FACTORS; SEX FACTORS; TIME FACTORS;

EID: 70350131710     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0909237106     Document Type: Article

References (47)

1. Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: What we know and what we need. Nat Med 7:552-556. (Pubitemid 32448321)
2. Antoniou AC, et al. (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21:1-18. (Pubitemid 32619211)
3. Hunter DJ, et al. (2005) A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 5:977-985.
4. Pharoah PD, Dunning AM, Ponder BA, Easton DF (2004) Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 4:850-860. (Pubitemid 39472952)
5. Bell DW, et al. (1999) Heterozygous germ-line hCHK2 mutations in Li-Fraumeni syndrome. Science 286:2528-2531. (Pubitemid 30026346)
6. Sodha N, et al. (2002) Increasing evidence that germ-line mutations in CHEK2 do not cause Li-Fraumeni syndrome. Hum Mutat 20:460-462. (Pubitemid 35453563)
7. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer:Acollaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet 74:1175-1182.
8. Friedrichsen DM, Malone KE, Doody DR, Daling JR, Ostrander EA (2004) Frequency of CHEK2 mutations in a population-based, case-control study of breast cancer in young women. Breast Cancer Res 6:R629-R635.
9. Kilpivaara O, et al. (2005) Correlation of CHEK2 protein expression and c. 1100delC mutation status with tumor characteristics among unselected breast cancer patients. Int J Cancer 113:575-580. (Pubitemid 40038733)
10. Rashid MU, et al. (2005) German populations with infrequent CHEK2*1100delC and minor associations with early-onset and familial breast cancer. Eur J Cancer 41:2896-2903.
11. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG (2007) Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol 25:57-63. (Pubitemid 350003051)
12. Meijers-Heijboer H, et al. (2002) Low-penetrance susceptibility to breast cancer due to CHEK2*1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31:55-59. (Pubitemid 34887638)
13. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG (2008) CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: Metaanalyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26:542-548. (Pubitemid 351264346)
14. Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3:421-429. (Pubitemid 38340288)
15. Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25:5912-5919. (Pubitemid 44453447)
16. 1 by stabilizing p53. Genes Dev 14:278-288.
17. Unger T, et al. (1999) Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2. EMBO J 18:1805-1814. (Pubitemid 29158524)
18. Shieh S-Y, Taya Y, Prives C (1999) DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. EMBO J 18:1815-1823. (Pubitemid 29158525)
19. Falck J, Mailand N, Syljuasen RG, Bartek J, Lukas J (2001) The ATM-Chk2-Cdc25A checkpoint pathway guards against radioresistant DNA synthesis. Nature 410:842-847. (Pubitemid 32303786)
20. Zhao H, Watkins JL, Piwnica-Worms H (2002) Disruption of the checkpoint kinase 1/cell division cycle 25A pathway abrogates ionizing radiation-induced S andG2 checkpoints. Proc Natl Acad Sci USA 99:14795-14800. (Pubitemid 35334563)
21. Mailand N, et al. (2000) Rapid destruction of human Cdc25A in response to DNA damage. Science 288:1425-1429. (Pubitemid 30366329)
22. Bahassi EM, et al. (2007) The breast cancer susceptibility allele CHEK2*1100delC promotes genomic instability in a knock-in mouse model. Mutat Res 616:201-209.
23. Anczuków O, et al. (2008) Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? Hum Mutat 29:65-73.
24. de Bock GH, et al. (2004) Tumor characteristics and prognosis of breast cancer patients carrying the germ-line CHEK2*1100delC variant. J Med Genet 41:731-735.
25. Dong X, et al. (2003) Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270-280. (Pubitemid 36194238)
26. Seppala EH, et al. (2003) CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 89:1966-1970. (Pubitemid 37533278)
27. Takai H, et al. (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J 21:5195-5205.
28. Jack MT, et al. (2002) Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci USA 99:9825-9829.
29. Hirao A, et al. (2002) Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner. Mol Cell Biol 22:6521-6532. (Pubitemid 34940968)
30. Kwak EL, et al. (2006) Mammary tumorigenesis following transgenic expression of a dominant negative CHK2 mutant. Cancer Res 66:1923-1928.
31. Coffey RJ, Jr, et al. (1994) Acceleration of mammary neoplasia in transforming growth factor α transgenic mice by 7,12- dimethylbenzanthracene. Cancer Res 54:1678-1683. (Pubitemid 24116169)
32. Ray D, et al. (2007) Hemizygous disruption of Cdc25A inhibits cellular transformation and mammary tumorigenesis in mice. Cancer Res 67:6605-6611.
33. Cangi MG, et al. (2000) Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest 106:753-761. (Pubitemid 30727593)
34. Ito Y, et al. (2004) Expression of cdc25A and cdc25B phosphatase in breast carcinoma. Breast Cancer 11:295-300.
35. Bonin S, Brunetti D, Benedetti E, Gorji N, Stanta G (2006) Expression of cyclin-dependent kinases and CDC25a phosphatase is related with recurrences and survival in women with peri- and post-menopausal breast cancer. Virchows Arch 448:539-544. (Pubitemid 44490550)
36. Thompson D, et al. (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97:813-822. (Pubitemid 40909124)
37. Xie S, et al. (2001) Plk3 functionally links DNA damage to cell cycle arrest and apoptosis at least in part via the p53 pathway. J Biol Chem 276:43305-43312. (Pubitemid 37371019)
38. Hassepass I, Voit R, Hoffmann I (2003) Phosphorylation at serine 75 is required for UV-mediated degradation of human Cdc25A phosphatase at the S-phase checkpoint. J Biol Chem 278:29824-29829. (Pubitemid 36962370)
39. Ben-Yosef T, Yanuka O, Halle D, Benvenisty N (1998) Involvement of Myc targets in c-myc and N-myc induced human tumors. Oncogene 17:165-171. (Pubitemid 28371889)
40. Galaktionov K, Chen X, Beach D (1996) Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382:511-517. (Pubitemid 26260686)
41. Xu X, et al. (2003) Overexpression of CDC25A phosphatase is associated with hypergrowth activity and poor prognosis of human hepatocellular carcinomas. Clin Cancer Res 9:1764-1772. (Pubitemid 36554602)
42. Marquez-Garban DC, Chen HW, Fishbein MC, Goodglick L, Pietras RJ (2007) Estrogen receptor signaling pathways in human nonsmall cell lung cancer. Steroids 72:135-143. (Pubitemid 46273500)
43. Bahassi EM, et al. (2008) The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage. Oncogene 27:3977-3985.
44. Hershberger PA, et al. (2005) Regulation of endogenous gene expression in human nonsmall cell lung cancer cells by estrogen receptor ligands. Cancer Res 65:1598-1605. (Pubitemid 40270190)
45. Stabile LP, et al. (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in nonsmall cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65:1459-1470.
46. Kawai H, et al. (2005) Combined overexpression of EGFR and estrogen receptor α correlates with a poor outcome in lung cancer. Anticancer Res 25:4693-4698. (Pubitemid 41729532)
47. Bocchinfuso WP, et al. (2000) Induction of mammary gland development in estrogen receptor-α knockout mice. Endocrinology 141:2982-2994. (Pubitemid 32250463)